Cargando…
Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection
The COVID‐19 pandemic caused by the novel coronavirus SARS‐CoV‐2 has resulted in more than 500 million cases and 6 million deaths. Several antiviral therapies and vaccines have been developed to mitigate the spread of this infection. However, new approaches are required to battle emerging SARS‐CoV‐2...
Autores principales: | Acharya, Arpan, Kutateladze, Tatiana G., Byrareddy, Siddappa N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137278/ https://www.ncbi.nlm.nih.gov/pubmed/35633739 http://dx.doi.org/10.1002/ctd2.66 |
Ejemplares similares
-
Catching BETs by viruses
por: Zandian, Mohamad, et al.
Publicado: (2022) -
Characterization of multiple interactions between the envelope E protein of SARS-CoV-2 and human BRD4
por: Zandian, Mohamad, et al.
Publicado: (2022) -
PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron
por: Acharya, Arpan, et al.
Publicado: (2022) -
SARS-CoV-2 Infection Leads to Neurological Dysfunction
por: Acharya, Arpan, et al.
Publicado: (2020) -
Drug Repurposing Approaches to Combating Viral Infections
por: Trivedi, Jay, et al.
Publicado: (2020)